Argos Reports Second Quarter 2017 Financial Results And Recent Operational Highlights

Published: Aug 10, 2017

DURHAM, N.C., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today reported financial results for the second quarter ended June 30, 2017 and provided an update on the Company’s recent corporate and operational highlights.

Back to news